Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Plos One|March 21, 2020
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutationsThomas T DeLeon, Daniel R Almquist, Benjamin R Kipp, et al.
Rare Tumors|October 5, 2017
Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell SarcomaJaime I Davila, Jason S Starr, Steven Attia, et al.
Journal for Immunotherapy of Cancer|November 29, 2016
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinomaBrian I Rini, David F McDermott, Hans Hammers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2012
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanomaJahan S Khalili, Shujuan Liu, Tania G Rodríguez-Cruz, et al.
European Urology|March 8, 2021
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical TrialThomas Powles, Michael B Atkins, Bernard Escudier, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Molecular Cancer Therapeutics|June 12, 2015
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream TeamPatricia M LoRusso, Scott A Boerner, Mary Jo Pilat, et al.
Plos One|November 14, 2013
An integrated model of the transcriptome of HER2-positive breast cancerKrishna R Kalari, Brian M Necela, Xiaojia Tang, et al.
Lancet (London, England)|July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Pageof 9